Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA on anticaries testing

This article was originally published in The Tan Sheet

Executive Summary

Agency affirms use of the human intra-oral test as a substitute for the animal test required in the OTC anticaries monograph in a response to the "numerous" letters it has received on the subject. The letter from CDER Office of Drug Evaluation V Director Robert DeLap, MD/PhD, says the agency believes "the criticisms of the intra-oral test" aired by the dental research community "are not sufficient to conclude that the use of this test as an alternative to the animal caries reduction test is unacceptable." FDA "will continue to accept petitions to allow these substitute tests and will review them on a product-specific basis," DeLap notes. FDA has allowed Tom's of Maine, which markets its products as not tested on animals, to use the alternative method, and denied a citizen petition from dental experts opposing the test (1"The Tan Sheet" Oct. 4, 1999, p. 23)

You may also be interested in...



FDA-Endorsed Use Of Non-Animal Toothpaste Test Reaffirmed By Agency

FDA's willingness to accept an intra-oral remineralization test for fluoride toothpaste as a substitute for a required animal test is reaffirmed by the agency in a recent letter to petitioners on the issue.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel